2 companies
UCB
Market Cap: €49.7b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€261.00
7D
3.7%
1Y
60.4%
argenx
Market Cap: €47.6b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€766.00
7D
7.0%
1Y
48.4%